China Dominates Rare Disease Trials in 2020

Since 2020, China has seen a significant increase in rare disease trials, surpassing even the US in this area. This notable shift could be due to a rise in funding allocated to these trials. Non-industry sponsored trials also play a crucial role, making up 55.6% of all rare disease trials since 2004.

These trials are essential because they focus on patient populations that may not attract significant financial investments from pharmaceutical companies. That’s where non-industry sponsors like academic institutions or government organizations step in. These sponsors are motivated by a desire to advance scientific knowledge and public health rather than profits.

Non-industry sponsors often have the expertise to navigate incentives and secure grants specifically for rare disease research. They may collaborate with industry partners to combine resources and knowledge, which is particularly important for diseases with limited patient populations.

In the Asia-Pacific region, there has been a notable increase in rare disease trials since 2017, surpassing North America in this area. This region’s dominance can be attributed to significant unmet medical needs and larger population sizes, making patient recruitment more accessible. Organizations like the Asia-Pacific cooperation are actively working to advance research and development for rare diseases in this region.

China, in particular, has emerged as a leader in rare disease trials since 2020. This success can be attributed to increased funding and streamlined processes for reviewing rare disease drugs, allowing for quicker access to the market. This progress demonstrates the growing importance of China in the global landscape of rare disease research and development.